홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Ammonium Chloride → 1-[4-(3-{[4-(Trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxamide

HRID 1028150
노트
인쇄 미리보기

반응식

HRID 1028150 반응식
[F:1][C:2]([F:31])([F:30])[C:3]1[CH:8]=[CH:7][N:6]=[C:5]([NH:9][C:10]2[CH:11]=[C:12]([C:16]3[N:17]=[C:18]([N:21]4[CH2:26][CH2:25][CH:24]([C:27](O)=[O:28])[CH2:23][CH2:22]4)[S:19][CH:20]=3)[CH:13]=[CH:14][CH:15]=2)[N:4]=1.[Cl-].[NH4+].C([N:37](C(C)C)CC)(C)C.F[P-](F)(F)(F)(F)F.N1(O[P+](N2CCCC2)(N2CCCC2)N2CCCC2)C2C=CC=CC=2N=N1>CN(C)C=O.C(OCC)(=O)C>[F:1][C:2]([F:31])([F:30])[C:3]1[CH:8]=[CH:7][N:6]=[C:5]([NH:9][C:10]2[CH:11]=[C:12]([C:16]3[N:17]=[C:18]([N:21]4[CH2:22][CH2:23][CH:24]([C:27]([NH2:37])=[O:28])[CH2:25][CH2:26]4)[S:19][CH:20]=3)[CH:13]=[CH:14][CH:15]=2)[N:4]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 4

HCID 25517Ammonium ChlorideHCID 81531DiisopropylethylamineHCID 2724699PyBOPHCID 683241951-[4-(3-{[4-(Trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylic acid

생성물 1

HCID 672365141-[4-(3-{[4-(Trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxamide수율 22.5%

시약·촉매·용매 2

HCID 6228Dimethylformamide용매HCID 8857Ethyl Acetate용매

실험 절차

To a solution of 1-[4-(3-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylic acid (36 mg, 0.08 mmol) in N,N-dimethylformamide (0.8 mL) was added ammonium chloride (13 mg, 0.24 mmol), diisopropylethylamine (56 L, 0.32 mmol), and (1H-benzotriazol-1-yloxy)(tripyrrolidin-1-yl)phosphonium hexafluorophosphate (83 mg, 0.16 mmol). The mixture was stirred for 60 minutes at room temperature. The mixture was diluted with ethyl acetate (30 mL), and washed with 1:1 saturated sodium bicarbonate:brine (30 mL), and 1:1 water:brine (30 mL). The aqueous fractions were further extracted with ethyl acetate (30 mL). The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by reverse phase HPLC to provide 8 mg (0.018 mmol, 22% yield) of 1-[4-(3-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxamide as a white solid. MS APCI: [M+H]+ m/z 449.1. 1H NMR (400 MHz, DMSO) δ 10.26 (s, 1H), 8.84 (d, J=4.8 Hz, 1H), 8.01 (s, 1H), 7.55-7.51 (m, 2H), 7.35-7.29 (m, 3H), 7.16 (d, J=7.6 Hz, 1H), 6.84 (s, 1H), 3.93 (m, 2H), 3.09 (m, 2H), 2.37 (m, 1H), 1.97-1.70 (m, 2H), 1.62 (m, 2H). rhSyk=++.

후처리

  1. washwashed with 1:1 saturated sodium bicarbonate
  2. extractionThe aqueous fractions were further extracted with ethyl acetate (30 mL)
  3. dry with materialThe combined organic extracts were dried over sodium sulfate
  4. concentrationconcentrated under reduced pressure
  5. customThe resulting residue was purified by reverse phase HPLC

출처 및 근거

ORD 기록
ord-c0e86ca9902b47e993baeeb1451495c9
출처 데이터셋
uspto-grants-2014_05
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08735417B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트